BibTex RIS Cite

-

Year 2014, , 70 - 73, 01.04.2014

Kaya B

https://doi.org/10.18521/ktd.48218

Abstract

Several tumor markers have been studied for early diagnosis of gastrointestinal tumors. While some of them are used in clinical practice, most are not cancer specific. CEA, AFP and CA 19-9 are most commonly used markers for gastrointestinal tumors. Pancreas adenocarcinoma is one of the serious malignities with a bad prognosis among gastrointestinal tumors. Most of the patients present with distant metastasis in time of diagnosis. Therefore, early diagnosis is still an important problem. CA 19-9 is most commonly used tumor marker in clinical practice. CA 19-9 is not specific for pancreas cancer and also increased in other gastrointestinal malignities and benign pathologies. New tumor markers have been researched for early diagnosis of pancreas cancer in last years. Beside CA 19-9, some oncogens and micro RNA’s are also still investigated. We aimed to summarize the diagnostic value of CA 19-9 and other tumor markers in pancreas adenocarcinoma with literature review

Keywords

Pancreas Adenocarcinoma Tumor Markers CA 19-9 micro RNA’s

References

  • 1. Ryu JK, Hong SM, Karikari CA et al. Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma. Pancreatology. 2010;10(1):66-73.
  • 2. Benson AB 3rd. Adjuvant therapy for pancreatic cancer: one small step forward. JAMA. 2007; 297(3):311- 3.
  • 3. Duffy MJ. CA 19-9 as a marker for gastrointestinal cancers: a review. Ann Clin Biochem. 1998;35(pt3):364-70.
  • 4. Lamerz R. Role of tumor markers, cytogenetics. Ann Oncol. 1999;10(4):145-9.
  • 5. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol. 1990; 85(4):350-5.
  • 6. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007; 33(3):266-70.
  • 7. Duffy MJ, Sturgeon C, Lamerz R et al. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol. 2010; 21(3):441-7.
  • 8. Albert MB, Steinberg WM, Henry JP. Elevated serum levels of tumor marker CA19-9 in acute cholangitis. Dig Dis Sci. 1988;33(10):1223-5.
  • 9. Ferrone CR, Finkelstein DM, Thayer SP et al. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 2006;24(18):2897-902.
  • 10. Turrini O, Schmidt CM, Moreno J et al. Very high serum CA 19-9 levels: a contraindication to pancreaticoduodenectomy? J Gastrointest Surg. 2009;13(10):1791-7.
  • 11. Garcea G, Neal CP, Pattenden CJ et al. Molecular prognostic markers in pancreatic cancer: a systematic review. Eur J Cancer. 2005; 41(15):2213-36.
  • 12. Mora J, Urgell E, Farré A et al. Agreement between K-ras sequence variations detected in plasma and tissue DNA in pancreatic and colorectal cancer. Clin Chem. 2006; 52(7):1448-9.
  • 13. Däbritz J, Hänfler J, Preston R et al. Detection of Ki-ras mutations in tissue and plasma samples of patients with pancreatic cancer using PNA-mediated PCR clamping and hybridisation probes. Br J Cancer. 2005; 31(2):405-12.
  • 14. Teich N, Mossner J. Molecular analysis of pancreatic juice: a helpful tool to differentiate benign and malignant pancreatic tumors? Dig Dis. 2004; 22(3):235-8.
  • 15. Mu DQ, Peng YS, Xu QJ. Values of mutations of K-ras oncogene at codon 12 in detection of pancreatic cancer: 15-year experience. World J Gastroenterol. 2004;10(4):471-5.
  • 16. Berndt C, Haubold K, Wenger F et al. K-ras mutations in stools and tissue samples from patients with malignant and nonmalignant pancreatic diseases. Clin Chem. 1998;44(10):2103-7.
  • 17. Zhu Z, Gao W, Qian Z, Miao Y. Genetic variation of miRNA sequence in pancreatic cancer. Acta Biochim Biophys Sin (Shanghai). 2009; 41(5):407-13.
  • 18. Torrisani J, Bournet B, du Rieu MC et al. Let-7 MicroRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression. Hum Gene Ther 2009; 20(8): 831-844
  • 19. Memişoğulları M, Orhan N. Paraoksonaz ve Kanser. Konuralp Tıp Dergisi 2010;2(2):22-26.

Pankreas Adenokarsinomu Tanısında Tümör Markırlarının Diyagnostik Değeri

Year 2014, , 70 - 73, 01.04.2014

Kaya B

https://doi.org/10.18521/ktd.48218

Abstract

Gastrointestinal tümörlerin erken tanısı ve takibinde birçok tümör markırı çalışılmıştır. Bu markırların bir kısmı klinik kullanım alanı bulmuş, ancak hiçbiri kansere spesifik özellik kazanamamıştır. Gastrointestinal sistem kanserlerinde CEA, AFP, CA 19–9 en sık kullanılan tümör markırları olmuştur. Pankreas adenokarsinomu gastrointestinal maligniteler içerinde kötü prognoza sahip lezyonlardan birisidir. Hastaların önemli bir bölümünde tanı sırasında uzak yayılım mevcuttur. Bu açıdan bakıldığında pankreas adenokarsinomunda erken tanı hala önemli bir sorundur. CA 19-9 klinik uygulamada pankreas kanseri tanısında en sık kullanılan tümör markırıdır. CA 19-9 pankreas kanseri için spesifik olmayıp, pankreas dışı gastrointestinal sistem maligniteleri ve benign hastalıklarda da yükselebilmektedir. Son yıllarda pankreas kanseri erken tanısında yeni tümör markırları araştırılmaktadır. CA 19–9 yanı sıra, çeşitli onkogenler ve mikro RNA’lar araştırma aşamasındadır. Bu çalışmamızda, CA 19–9 ve diğer tümör markırlarının pankreas adenokarsinomu tanısındaki değerini güncel literatür taraması ile birlikte ortaya koymayı amaçladık

Keywords

Pankreas Adenokanseri Tümör Markırları CA 19–9 mikro RNA’lar

References

  • 1. Ryu JK, Hong SM, Karikari CA et al. Aberrant MicroRNA-155 expression is an early event in the multistep progression of pancreatic adenocarcinoma. Pancreatology. 2010;10(1):66-73.
  • 2. Benson AB 3rd. Adjuvant therapy for pancreatic cancer: one small step forward. JAMA. 2007; 297(3):311- 3.
  • 3. Duffy MJ. CA 19-9 as a marker for gastrointestinal cancers: a review. Ann Clin Biochem. 1998;35(pt3):364-70.
  • 4. Lamerz R. Role of tumor markers, cytogenetics. Ann Oncol. 1999;10(4):145-9.
  • 5. Steinberg W. The clinical utility of the CA 19-9 tumor-associated antigen. Am J Gastroenterol. 1990; 85(4):350-5.
  • 6. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol. 2007; 33(3):266-70.
  • 7. Duffy MJ, Sturgeon C, Lamerz R et al. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol. 2010; 21(3):441-7.
  • 8. Albert MB, Steinberg WM, Henry JP. Elevated serum levels of tumor marker CA19-9 in acute cholangitis. Dig Dis Sci. 1988;33(10):1223-5.
  • 9. Ferrone CR, Finkelstein DM, Thayer SP et al. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 2006;24(18):2897-902.
  • 10. Turrini O, Schmidt CM, Moreno J et al. Very high serum CA 19-9 levels: a contraindication to pancreaticoduodenectomy? J Gastrointest Surg. 2009;13(10):1791-7.
  • 11. Garcea G, Neal CP, Pattenden CJ et al. Molecular prognostic markers in pancreatic cancer: a systematic review. Eur J Cancer. 2005; 41(15):2213-36.
  • 12. Mora J, Urgell E, Farré A et al. Agreement between K-ras sequence variations detected in plasma and tissue DNA in pancreatic and colorectal cancer. Clin Chem. 2006; 52(7):1448-9.
  • 13. Däbritz J, Hänfler J, Preston R et al. Detection of Ki-ras mutations in tissue and plasma samples of patients with pancreatic cancer using PNA-mediated PCR clamping and hybridisation probes. Br J Cancer. 2005; 31(2):405-12.
  • 14. Teich N, Mossner J. Molecular analysis of pancreatic juice: a helpful tool to differentiate benign and malignant pancreatic tumors? Dig Dis. 2004; 22(3):235-8.
  • 15. Mu DQ, Peng YS, Xu QJ. Values of mutations of K-ras oncogene at codon 12 in detection of pancreatic cancer: 15-year experience. World J Gastroenterol. 2004;10(4):471-5.
  • 16. Berndt C, Haubold K, Wenger F et al. K-ras mutations in stools and tissue samples from patients with malignant and nonmalignant pancreatic diseases. Clin Chem. 1998;44(10):2103-7.
  • 17. Zhu Z, Gao W, Qian Z, Miao Y. Genetic variation of miRNA sequence in pancreatic cancer. Acta Biochim Biophys Sin (Shanghai). 2009; 41(5):407-13.
  • 18. Torrisani J, Bournet B, du Rieu MC et al. Let-7 MicroRNA transfer in pancreatic cancer-derived cells inhibits in vitro cell proliferation but fails to alter tumor progression. Hum Gene Ther 2009; 20(8): 831-844
  • 19. Memişoğulları M, Orhan N. Paraoksonaz ve Kanser. Konuralp Tıp Dergisi 2010;2(2):22-26.
There are 19 citations in total.

Details

Primary Language Turkish
Journal Section Articles
Authors

Kaya B This is me

Publication Date April 1, 2014
Published in Issue Year 2014

Cite

APA B, K. (2014). Pankreas Adenokarsinomu Tanısında Tümör Markırlarının Diyagnostik Değeri. Konuralp Medical Journal, 6(1), 70-73. https://doi.org/10.18521/ktd.48218
AMA B K. Pankreas Adenokarsinomu Tanısında Tümör Markırlarının Diyagnostik Değeri. Konuralp Medical Journal. April 2014;6(1):70-73. doi:10.18521/ktd.48218
Chicago B, Kaya. “Pankreas Adenokarsinomu Tanısında Tümör Markırlarının Diyagnostik Değeri”. Konuralp Medical Journal 6, no. 1 (April 2014): 70-73. https://doi.org/10.18521/ktd.48218.
EndNote B K (April 1, 2014) Pankreas Adenokarsinomu Tanısında Tümör Markırlarının Diyagnostik Değeri. Konuralp Medical Journal 6 1 70–73.
IEEE K. B, “Pankreas Adenokarsinomu Tanısında Tümör Markırlarının Diyagnostik Değeri”, Konuralp Medical Journal, vol. 6, no. 1, pp. 70–73, 2014, doi: 10.18521/ktd.48218.
ISNAD B, Kaya. “Pankreas Adenokarsinomu Tanısında Tümör Markırlarının Diyagnostik Değeri”. Konuralp Medical Journal 6/1 (April 2014), 70-73. https://doi.org/10.18521/ktd.48218.
JAMA B K. Pankreas Adenokarsinomu Tanısında Tümör Markırlarının Diyagnostik Değeri. Konuralp Medical Journal. 2014;6:70–73.
MLA B, Kaya. “Pankreas Adenokarsinomu Tanısında Tümör Markırlarının Diyagnostik Değeri”. Konuralp Medical Journal, vol. 6, no. 1, 2014, pp. 70-73, doi:10.18521/ktd.48218.
Vancouver B K. Pankreas Adenokarsinomu Tanısında Tümör Markırlarının Diyagnostik Değeri. Konuralp Medical Journal. 2014;6(1):70-3.